Abstract Osteosarcoma is the most common primary malignant bone tumor, accounting for approximately 20% of all primary sarcomas in bone. Although treatment modalities have been improved over the past decades, it is still a tumor with a high mortality rate in children and young adults. Based on histological considerations, osteosarcoma arises from impaired differentiation of these immature cells into more mature types and that correction of this impairment may reduce malignancy and increase the efficiency of chemotherapy. The purpose of this study was to determine the effect of specific inhibitors of MAPK extracellular signaling-regulated kinase (ERK) kinase (MEK) and p38 on the differentiation of human osteosarcoma cell line SaOS-2 cells. We found that PD98059, a specific inhibitor of MEK, inhibited the serum-stimulated proliferation of SaOS-2 cells; whereas SB203580, a specific inhibitor of p38 MAPK, had little effect on it. SB203580 suppressed ALPase activity, gene expression of type I collagen, and expression of ALP and BMP-2 mRNAs; whereas PD98059 upregulated them dose dependently. In addition, immunoblot and immunostaining analysis revealed that phosphorylation of ERK was increased by treatment with SB203580; whereas PD98059 increased the phosphorylation of p38, which implies a seesaw-like balance between ERK and p38 phosphorylation. We suggest that osteosarcoma cell differentiation is regulated by the balance between the activities of the ERK and p38 pathways and that the MEK/ERK pathway negatively regulates osteosarcoma cell differentiation, whereas the p38 pathway does so positively. MEK inhibitor may thus be a good candidate for altering the expression of the osteosarcoma malignant phenotype.
Background
Osteosarcoma is the most frequent primary bone tumor (Goorin et al. 1985) , and it has a marked tendency to recur and metastasize to the lungs and skeleton (Lane et al. 1986 ). It originates from undifferentiated mesenchymal cells and consists of osteoblastic, chondroblastic, and fibroblastic cells or their combination. These histologic features suggest that osteosarcoma arises from impaired differentiation of these immature cells into more mature types and that correction of this impairment may reduce malignancy and increase the efficiency of chemotherapy. Therefore, differentiation induction holds great potential as a new modality of cancer therapy (Hozumi 1983) .
Mitogen-activated protein kinases (MAPKs) are prolinedirected serine-threonine kinases that have important functions as mediators of cellular responses to a variety of extracellular stimuli (Cano and Mahadevan 1995; Marshall 1995) . Extracellular zsignal-regulated kinases (ERKs) are characteristically activated by various growth factors. Members of the p38 MAPK (p38) and c-Jun N-terminal kinase (JNK) subfamilies are strongly activated in response to stress stimuli Kyriakis et al. 1994 ) and thus proinflammatory cytokines, and have been given the name stress-activated protein kinases (SAPKs). Whereas the ERK pathway is usually associated with cell proliferation and protection from apoptosis, p38 and JNK ones can promote apoptosis in many systems (Xia et al. 1995) . Recent studies suggest that, in addition to its effect on apoptosis, the p38 pathway might also be involved in the differentiation of neural cells (Iwasaki et al. 1999) , adipocytes (Engelman et al. 1998) , and chondrocytes (Yoshimichi et al. 2001; Shimo et al. 2005) . In osteoblast-like cells, activation of ERK has been reported in response to several growth factors including mitogens acting through receptor tyrosine kinases (RTKs) such as basic fibroblast growth factor (bFGF; Suzuki et al. 2000) , epidermal growth factor (EGF; Matsuda et al. 1998) , platelet-derived growth factor (PDGF; Chaudhary and Avioli 1997) , and insulin-like growth factor-1 (IFG-1; Kawane and Horiuchi 1999) . As reported to be its effect in other cell systems, activation of ERK in osteoblast-like cells by growth factors is associated with enhanced cell proliferation. However, recent data have suggested that ERK might also be involved in the regulation of bone cell differentiation (Kawamura et al. 1999; Tokuda et al. 1999) . Whereas studies using MC3T3-E1 cells suggest that activation of p38 is critical for ALP expression induced by fetal bovine serum (Suzuki et al. 2002) . Differentiation of the bone marrow osteoprecursors was also inhibited in terms of ALP by a p38 inhibitor (Hu et al. 2003) . In the present study, we investigated the effect of specific inhibitors of MEK and p38 on the differentiation of SaOS-2 cells and found that the MEK inhibitor enhanced and accelerated the differentiation but that the p38 inhibitor suppressed it. In addition we observed a seesaw-like phosphorylation between ERK and p38 when the cells were treated with the inhibitor for MEK or p38.
Results

Effect of ERK and p38 MAPK inhibitors on the proliferation of SaOS-2 cells
Growth factors contained in FBS have been shown to play a critical role in the growth and differentiation of SaOS-2 cells (Bruserud et al. 2005) . It is well documented that many growth factors can lead to the stimulation of different MAP kinases. To determine whether activation of ERK was required for serum-stimulated SaOS-2 cell proliferation, we incubated SaOS-2 cells in fresh αMEM+10% FBS in the presence of the ERK-specific MEK1/2 inhibitor PD98059 (20 μM; Williamson et al. 2004 ). This inhibitor blocked the serum-stimulated proliferation of the cells; whereas incubation with the specific p38 inhibitor, SB203580 (Bebien et al. 2003) , at 20 μM had little effect on the up-regulation of proliferation by serum (Fig. 1a) .
Inhibition of ERK stimulated ALPase activity in SaOS-2 cells
To determine whether activation of ERK and p38 was required for SaOS-2 cell differentiation, we stimulated SaOS-2 cells with fresh αMEM+10% FBS in the presence of 10 or 20 μM PD98059 or SB203580 for 48 h. Treatment with SB203580 inhibited the ALPase activity dose dependently (Fig. 1b) . In contrast, ALPase activity in the presence of PD98059 at 20 μM was up-regulated (Fig. 1b) , which concentration is sufficient to inhibit the ERKs in calvarial osteoblasts (Li et al. 2002) and SaOS-2 cells (Juretic et al. 2001 ).
Effect of ERK and p38 MAPK inhibitors on the mineralization of SaOS-2 cells
To investigate whether activation of ERK and p38 was required for formation of mineralized bone nodules by SaOS-2 cells, these cells treated with 20 μM PD98059 or SB203580 were cultured in the presence of 50 μg/ml ascorbic acid and 10 mM β-glycerophosphate (β-GP) for 10 days. SaOS-2 cells treated with PD98059 showed marked mineralization, whereas SB203580 treated cells mineralization was inhibited compared to the control culture (Fig. 1c) .
MEK inhibitor enhanced and accelerated the differentiation in SaOS-2 cells To determine whether activation of ERK and p38 was required for the early to late stage of SaOS-2 cell differentiation, we compared the mRNA expression of type I collagen, ALP, and osteocalcin in the presence of PD98059 or SB203580 with that in fresh 10% FBS culture medium. PD98059 up-regulated type I collagen, ALP, and osteocalcin mRNA levels dose dependently; whereas increasing amounts of SB203580 suppressed those of type I collagen, ALP, and osteocalcin ( Fig. 2a-c) , indicating that activation of ERK inhibited early and late stages of SaOS-2 cell differentiation, whereas p38 stimulated them. However, type I collagen, ALP, and osteocalcin mRNA expression were not changed by PD98059 or SB203580 in the absence of serum ( Fig. 3a-d ). Bone morphogenetic proteins (BMPs) are members of transforming growth factor-β (TGF-β) family that play essential role in osteogenesis (Urist 1965) . Treatment with 20 μM PD98059 for 24 or 48 h upregulated BMP-2 mRNA expression, whereas that with SB203580 suppressed it (Fig. 2d ).
Cross-talk between ERK and p38
New at al. (New et al. 2001 ) recently reported similar results; i.e., they observed the enhancement of ERK phosphorylation by treatment with SB203580 in PC12 cells in the presence of epidermal growth factor (EGF). Their finding prompted us to investigate the possibility of cross-talk between ERK and p38. Phosphorylation of ERK and p38 was increased 12 h after changing the culture medium to fresh αMEM containing 10% FBS (Fig. 3a) .
SaOS-2 cells were incubated with various concentrations of PD98059 or SB203580 in the presence of fresh αMEM containing 10% FBS and subjected to immunoblot analysis with anti-phospho-ERK and anti-phospho-p38. The phosphorylation of ERK was markedly decreased by PD98059 but clearly increased in the presence of SB203580, both time and dose dependently ( Fig. 3b and c) . On the other hand, phosphorylation of p38 was markedly suppressed by SB203580 but up-regulated in the presence of PD98059, in a time and dose-dependent manner ( Fig. 3d and e) . As shown in Fig. 4 , the expression of phosphorylated ERK was markedly decreased by PD98059 (Fig. 4e) but markedly increased by SB203580 (Fig. 4f) . On the other hand, the phosphorylation of p38 was suppressed by SB203580 ( Fig. 4j ) but up-regulated by PD98059 (Fig. 4i) . However, PD98059 and SB203580 failed to --
Possible cross-talk between ERK and p38. a SaOS-2 cells were cultured for 7 days in complete α MEM containing 10% FBS. Then, the cells were either kept in the same medium or changed with fresh αMEM+10% FBS; and 12 h later the cells were subjected to immunoblotting using anti-p-ERK or anti-p-p38. b-f SaOS-2 cells were cultured for 7 days in complete αMEM containing 10% FBS. Then, the cells were either kept in the same medium (b) or changed with fresh αMEM+10% FBS culture medium (c-f); and 12 h later they were then treated with 20 μM PD98059 or SB203580 for the indicated times (c and e) or with various concentrations of PD98059 or SB203580 for 60 min (d and f). Cell lysate were processed for immunoblot determination of total ERK (c and d) and total p38 (e and f) or levels of phosphorylated ERK (c and d) and p38 (e and f), which are indicated as p-ERK and p-p38, respectively. The data from a typical experiment are presented; similar results were obtained in 3 separate experiments influence p38 and ERK closs-talk activation, respectively, in the absence of serum (Fig. 3b) . Taken together, our data show that the p38 inhibitor increased the phosphorylation of ERK, and the MEK inhibitor increased that of p38 in compete culture medium containing 10% FBS.
Discussion
In this report, the effects of MEK and p38 inhibitors on the differentiation of SaOS-2 cells were investigated. The MEK inhibitor markedly enhanced differentiation in the presence of serum, whereas the p38 inhibitor suppressed it. Activation of these signaling pathways in differentiating SaOS-2 cells after addition of fresh culture medium containing 10% FBS is mediated by factors contained in the serum, because no stimulation of these MAPKs was detected when fresh culture medium containing no FBS was used (data not shown). Osteosarcoma cells at different osteoblastic stages display many of the features of differentiated osteoblasts, and the signal transduction pathway for osteosarcoma differentiation has been studied. Several research groups have investigated the involvement of MAPKs in this signaling pathway (Suzuki et al. 2002; Hu et al. 2003) . As mentioned earlier, ERK is activated by growth factors acting through different types of receptors and mediates their mitogenic effects in bone-forming cells. As expected from this information, inhibiting the stimulation of ERK in response to FBS in proliferating SaOS-2 cells stopped their [ 3 H] thymidine incorporation (Fig. 1a) , thus confirming the importance of this pathway in regulating SaOS-2 cell proliferation. We also demonstrated that ERKs played a negative role in serum-induced SaOS-2 cell differentiation. Blockage of MEK1/2 with the specific inhibitor PD98059 had a significant promotive effect on SaOS-2 cell differentiation. Our results are not in agreement with the findings that expression of dominant-negative ERK1 inhibited not only human osteoblast differentiation, but also proliferation, cell spreading, and migration (Lai et al. 2001) . One explanation for the discrepancy is the cell source. Osteoblasts isolated from human bone chips were used in the experiments just cited, whereas we used a human osteosarcoma cell line. Another possibility is the difference between the inhibitor and the dominant-negative form of ERK1. (a-l) SaOS-2 cells were cultured for 4 days in complete αMEM containing 10% FBS, and then the medium was changed to fresh αMEM+10% FBS for 12 h, after which the cells were treated with vehicle (a-d), 20 μM PD98059 (e-h), or SB203580 (i-k) for 60 min. The cells were immunostained for phosphorylated ERK (a, e, and i) phosphorylated p38 (b, f, and j) and DAPI (c, g, and k) and then photographed under a microscope. d, h, and l: merged image of phase-contrast microscopic views in "a-c", in "e-g" and in "i-k" respectively. Bar: 50 μm Dominant-negative ERK1 suppressed the cellular differentiation, whereas PD98059 accelerated it. It is likely that PD98059 positively affected the p38 signaling pathwayinduced differentiation. Possible "seesaw-talk" between ERK and p38 signals may be proposed, which is discussed later on herein.
On the other hand, inhibition of p38 by its specific inhibitor, SB203580, interfered with the differentiation process of SaOS-2 cells. All of the differentiation markers, including type 1 collagen, ALP, and osteocalcin mRNAs, were reduced in the presence of the p38 inhibitor. These data suggest that activation of p38 is necessary for SaOS-2 cell differentiation. This suggestion is further supported by the fact that p38 MAPK is activated at the early stage of osteoblast differentiation (Suzuki et al. 2002) . Furthermore, inhibition of p38 activity was associated with a slight increase in SaOS-2 cell proliferation, indicating that the p38 pathway is probably not involved in mediating the growth arrest that precedes the onset of SaOS-2 cell differentiation. However, inhibition of JNK by SP600125 was not associated with ALP and osteocalcin mRNAs when fresh culture medium containing 10% FBS was used (data not shown). Indeed, SP600125 could not mediate the ALP and osteocalcin production in normal culture condition, but associated with small effects on ALP, and a marked and consistent decrease in osteocalcin production in response to BMP-2 in both MC3T3-E1 and calvaria cells (Guicheux et al. 2003) . Taken together, these observations indicate that the JNK is implicated in BMP-2-induced osteoblastic cell differentiation with distinct regulatory effects on ALP and OC expression.
SaOS-2 cell differentiation is stimulated by local factors such as BMPs (Huang et al. 2002) . Inhibition of p38 caused a delay in SaOS-2 cell differentiation. This delay may be partially released by the presence of BMP-2, suggesting that BMP-2 is able to overcome the loss of signals from p38 during SaOS-2 cell differentiation. Activation of p38 by BMP-2 is involved in ALP and osteocalcin expression (Guicheux et al. 2003) . BMPs control osteoblast differentiation through Smad proteins that are inhibited by Tob (Yoshida et al. 2000) . Activation of the BMP-Smad pathway may somehow compensate for the loss of p38. Further experiments will be needed to investigate the mechanism.
Immunoblot analysis using antibodies against phosphorylated MAP kinases revealed a "seesaw-talk" between ERK and p38: i.e., the MEK inhibitor caused a decrease in the level of phosphorylated ERK with an increase in that of phosphorylated p38, whereas the p38 inhibitor had the opposite effects. A similar seesaw cross-talk was previously reported, in which SB203580 by itself did not affect the activity of ERK but significantly extended EGF-induced ERK activation in PC12 cells (New et al. 2001 ). In RAW264.7 cells, seesaw-like phosphorylation between ERK and p38 was observed when the cells were treated with inhibitors for MEK and p38 in the presence of RANKL (Bruserud et al. 2005) . It is unlikely that secondary products derived from transcripts by transcription factors downstream of a MAPK pathway affected the other MAPK pathway, because the enhancement of phosphorylation by MAPK inhibitors took place after only 30 min. Previous studies have shown that SB203580 inhibits Raf production but paradoxically stimulates Raf activity (Hall-Jackson et al. 1999) . This phenomenon could be due to a negative-feedback mechanism by which Raf inhibits itself. It is also known that SB239069, another highly selective p38 inhibitor, which does not inhibit Raf (Underwood et al. 2000) , also increased H 2 O 2 -stimulated ERK phosphorylation (Liu and Hofmann 2004) . Thus it is thus unlikely that the effect of SB203580 on ERK phosphorylation was due to its effect on Raf. A recent study demonstrated that activation of p38 can block the ERK pathway at the level of MEK through activation of protein phosphatase 2A (pp2A; Westermarck et al. 2001 ). Furthermore, SB203580 enhanced H 2 O 2 -stimulated ERK phosphorylation via pp2A in cardiac ventricular myocytes (Liu and Hofmann 2004) . On the other hand, MAPK phosphatase (MKP)-1 is known to be up-regulated by ERK and to preferentially inactivate p38. PD98059 enhanced lipopolysaccharide-stimulated, p38 phosphorylation via MKP-1 in Raw 264.7 cells (Hotokezaka et al. 2002) . Such findings may not be directly linked to the results in this study, but suggest the possibility that the chemical inhibitors may affect more than one molecule.
In conclusion, MEK inhibitor PD98059 suppressed serum-induced proliferation and up-regulated the differentiation of osteosarcoma cells. Further studies are needed to clarify the reciprocal effects of MAPK inhibitors on differentiation in SaOS-2 cells (Fig. 5) and to elucidate the seesaw cross-talk mechanism by which the inhibition of ERK or p38 phosphorylation by MEK or p38 inhibitors conversely induces p38 and ERK phosphorylation. Fig. 5 Scheme showing the seesaw cross-talk, between MEK/ERK and p38 pathways during the differentiation of Saos-2 cells. Growth factors contained in FBS activate both ERK and p38 pathways. The MEK/ERK pathway suppresses differentiation and is inhibited by PD98059. In contrast, the p38 pathway enhances differentiation and is inhibited by SB203580. PD98059 inhibits ERK and activates p38, whereas SB203580 inhibits p38 and activates ERK
Materials and methods
Materials
The alpha modification of Eagle's medium (αMEM) was purchased from Invitrogen Corporation (Grand Island, NY); and fetal bovine serum (FBS), from JRH Bioscience (Lenexa, KS). Plastic dishes and plates were from Becton Dickinson (Frabkin Lakes, NJ). P-nitrophenyl phosphate (p-NPP) and p-nitrophenol (p-NP) were purchased from Wako Pharmaceuticals (Osaka, Japan). [ 3 H] Thymidine was obtained from Amersham Pharmacia Biotech (Aylesbury, UK). PD98059 and SB203580 came from Calbiochem (La Jolla, Ca). Anti-ERK1/2, p-ERK1/2, p38 and p-p38 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Cell culture
Human osteosarcoma cell line SaOS-2 cells were inoculated at a density of 1×10 6 cells/60-mm-diameter dish, 2×10 5 cells/ well in 12-well multiplates, and 2×10 4 cells/ well in 96-well multiplates. These cells were cultured in αMEM containing 10% FBS. All cells were cultured in 5% CO 2 in an atmosphere of 37°C. 
Alkaline phosphatase activity
For estimation of ALPase activity, SaOS-2 cells was grown to confluence in 24-well multiplates with αMEM containing 10% FBS. Then the cells were either kept in the same medium or the medium was exchanged for fresh αMEM+ 10%FBS containing 10 or 20 μM PD98059 or SB203580 and incubated for 48 h. After the incubation, the cells were rinsed with ice-cold phosphate-buffered saline (PBS), homogenized in 0.5 M Tris (pH 9.0) containing 0.9% NaCl and 1% Triton X-100 on ice, and centrifuged at 12,000 g for 15 min. ALPase activity in the resultant supernatants was determined by the method of Bessey (Bessey et al. 1946 ) with some modifications. The enzyme reaction was initiated with 0.5 mM p-NPP in 0.5 M Tris-HCl (pH 9.0) containing 0.5 mM MgCl 2 at 37°C and terminated by the addition of a quarter volume of 1 M NaOH. The concentration of p-NP generated was determined by spectrophotometry at 410 nm, and the enzyme activity was expressed as nmol p-NPP cleaved per minute per well.
Mineralization assay
Cells were inoculated at a density of 1×10 5 cells/well in 24-well multiplates and were cultured until confluent with MEM containing 10% FBS. SaOS-2 cells were cultured in complete αMEM containing 10% FBS, 50 μg/ml ascorbic acid and 10 mM β-GP in the presence of 20 μM PD98059 or SB203580 for 10 days. The cells were fixed in 95% ethanol for 15 min at 37°C, washed with PBS, and stained with 1% alizarin red for 5 min at room temperature. DMSO was added to control cultures.
Immunoblot analysis
SaOS-2 monolayer cultures were rinsed with ice-cold PBS and lysed in ice-cold lysis buffer (50 mM Tris-HCl, pH 7.4, containing 150 mM NaCl, 1% Triton X-100, 1% NP-40, 10 mM NaF, 100 μM leupeptin, 2 μg/ml aprotinin, and 1 mM phenylmethyl sulfonyl fluoride) on ice. Cell lysates containing 10 μg of total protein in lysis buffer were electrophoresed in 12% SDS-PAGE gels (READYGELS, BIO-RAD) and the proteins were transferred to nylon membranes. The membranes were blocked with 2% nonfat dry milk in TBS overnight at 4°C and then incubated with a 1:200 dilution of anti-p-ERK1/2, ERK1/2, p-p38 or p38 antibodies. Horseradish peroxidase-conjugated goat antirabbit or goat anti-mouse IgG were used as the secondary antibodies at a 1:1,000 dilution. Bands were visualized by using the ECL chemiluminescence detection method (RPN2109, Amersham Biosciences, UK).
Quantitative real-time RT-PCR Total RNA was isolated using TRIzol reagent (Life Technologies Inc.), according to the manufacturer's instructions. Complementary DNA was generated from 1 μg of total RNA using the First Strand cDNA Synthesis Kit (Invitrogen) in a final volume of 20 μl. Real-time RT-PCR was performed with a Light Cycler (Roche Molecular Biochemicals, Mannheim, Germany) in Light Cycler capillaries using a commercially available master mix containing Taq DNA polymerase and SYBR-Green I deoxyribonucleoside triphosphates (Light Cycler DNA master SYBR-Green I, Roche Molecular Biochemicals). After the addition of primers, MgCl 2 (3 mM), and template DNA to the master mix, 65 cycles of denaturation (95°C for 10 s), annealing, (55°C for 5 s) and extension (72°C for 10 s) were performed. Primers used were the following: 5′-CAGACTGGCAACCTCAA GAA-3′ and 5′-GGAGGTCTTGGTGGTTTTGT-3′ for type I collagen; 5′-CCCCGTGGCAACTCTATCTT-3′ and 5′-CTGCGCCTGGTAGTTGTTGT-3′ for ALP; 5′-GAGGG CAGCGAGGTAGTGAA-3′ and 5′-TCCTGAAAGCC GATGTGGTC-3′ for osteocalcin; 5′-ATGCTAGACCTG TATCGC and 5′-TCGTTTCTGGTAGTTCTTCC-3′for BMP-2; and 5′-TGAACGGGAAGCTCACTGG-3′ and 5′-TCCACCACCCTGTTGCTGTA-3′ for GAPDH. After the completion of PCR amplification, a melting curve analysis was performed. The fluorescence intensity of the doublestrand-specific SYBR Green I, reflecting the amount of formed PCR product, was monitored at the end of each elongation step. GAPDH mRNA levels were used to normalize the cDNA content of the samples.
Immunofluorescence analysis
After growth on culture slides, SaOS-2 cells were washed with PBS and fixed 20 min with cold methanol, and then permeabilized in 0.1% NP-40 in PBS. After the fixed cells had been washed three times with PBS, they were incubated at 4°C overnight with the desired primary antibody in 3% BSA-PBS. Then, the sections were washed three times with PBS and thereafter reacted with fluorescein isothiocyantate (FITC) or rodamine-conjugated anti-rabbit or anti-mouse IgG serum in 3% bovine serum albumin (BSA)-PBS for 1 h. The sections were finally washed three times with PBS, and were mounted and viewed under a fluorescence microscope (IX81, Olympus, Tokyo, Japan).
Statistical analysis
Data were analyzed by using the Fisher's protected least significant difference (Fisher's PLSD) for analysis of multiple group comparisons. Results were expressed as the mean±S.D. p<0.05 was considered statistically significant.
